Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPFZ.L Regulatory News (PFZ)

  • There is currently no data for PFZ

Form 8.3 - Allergan Plc

16 Nov 2015 14:28

RNS Number : 8642F
Northern Trust Corporation
16 November 2015
Β 

ο»Ώ

Β 

FORMΒ 8.3

Β 

IRISHΒ TAKEOVERΒ PANEL

Β 

DISCLOSUREΒ UNDERΒ RULEΒ 8.3Β OFΒ THEΒ IRISHΒ TAKEOVERΒ PANEL ACT,Β 1997,Β TAKEOVERΒ RULES,Β 2013

Β 

DEALINGSΒ BYΒ PERSONSΒ WITHΒ INTERESTSΒ INΒ RELEVANTΒ SECURITIESΒ REPRESENTINGΒ 1%Β ORΒ MORE

Β 

1. KEYΒ INFORMATION

Β 

Name of person dealing (Note 1)

Northern Trust Group

Company dealt in

Allergan Plc

Class of relevant security to which the dealings being disclosed relate (Note 2)

Ordinary Shares

Date of dealing

13th November 2015

Β 

2. INTERESTSΒ ANDΒ SHORTΒ POSITIONS*

Β 

(a) InterestsΒ andΒ shortΒ positionsΒ (followingΒ dealing)Β inΒ theΒ classΒ ofΒ relevantΒ securityΒ dealtΒ inΒ (NoteΒ 3)

Long

Short

Number

(%)

Number

(%)

(1) Relevant securities

4,457,345 1.13

(2) Derivatives (other than options)

(3) Options and agreements to purchase/sell

Total

4,457,345 1.13

* Note: The difference in holdings from yesterday and today not explained by transactions, can be explained by stock transfers of 1,185securities out of the relevant accounts

Β 

(b) InterestsΒ andΒ shortΒ positionsΒ inΒ relevantΒ securitiesΒ ofΒ theΒ company,Β otherΒ thanΒ theΒ classΒ dealtΒ inΒ (NoteΒ 3)

Class of relevant security:

Long

Short

Number

(%)

Number

(%)

(1) Relevant securities

Β 

(2) Derivatives (other than options)

Β 

(3) Options and agreements to purchase/sell

Total

Β 

3. DEALINGSΒ (NoteΒ 4)

Β 

(a) PurchasesΒ andΒ sales

Β 

Β 

Purchase/sale

Β 

Number of relevant securities

Β 

Price per unit (USD)

Buy

189

299.63

Buy

38

300.00

Buy

34

300.63

Buy

95

302.26

Buy

24

302.64

Sell

2

302.47

Sell

20

302.67

Sell

40

304.28

Buy

2

300.91

Β 

Sell

7

301.00

Β 

Β 

(b) DerivativesΒ transactionsΒ (otherΒ thanΒ optionsΒ transactions)

Β 

Product name,

e.g. CFD

Nature of transaction

(Note 6)

Number of relevant securities

(Note 7)

Price per unit

(Note 5)

Β 

(c) OptionsΒ transactionsΒ inΒ respectΒ ofΒ existingΒ relevantΒ securities

Β 

Β 

(i) Writing,Β selling,Β purchasingΒ orΒ varying

Β 

Product name,

e.g. call option

Writing, selling, purchasing, varying etc.

Number of securities to which the option relates (Note 7)

Exercise price

Type, e.g. American, European etc.

Expiry date

Option money paid/received per unit (Note 5)

Β 

(ii) Exercising

Β 

Product name,

e.g. call option

Number of securities

Exercise price per unit (Note 5)

Β 

(d) OtherΒ dealingsΒ (includingΒ transactionsΒ inΒ respectΒ ofΒ newΒ securities)Β (NoteΒ 4)

Β 

Nature of transaction

(Note 8)

Details

Price per unit

(if applicable) (Note 5)

Β 

4. OTHERΒ INFORMATION

Β 

Agreements,Β arrangementsΒ orΒ understandingsΒ relatingΒ toΒ optionsΒ orΒ derivatives

Β 

FullΒ detailsΒ ofΒ anyΒ agreement,Β arrangementΒ orΒ understandingΒ betweenΒ theΒ personΒ disclosing andΒ anyΒ otherΒ personΒ relatingΒ toΒ theΒ votingΒ rightsΒ ofΒ anyΒ relevantΒ securitiesΒ underΒ anyΒ option referredΒ toΒ onΒ thisΒ formΒ orΒ relatingΒ toΒ theΒ votingΒ rightsΒ orΒ futureΒ acquisitionΒ orΒ disposalΒ ofΒ anyrelevantΒ securitiesΒ toΒ whichΒ anyΒ derivativeΒ referredΒ toΒ onΒ thisΒ formΒ isΒ referenced.Β IfΒ none,Β thisshouldΒ beΒ stated.

Β 

Β 

Β 

N/A

Β 

Β 

Β 

Β 

IsΒ aΒ SupplementalΒ FormΒ 8Β attached?Β (NoteΒ 9) Β NO

Β 

Date of disclosure

Β 16th November 2015

Contact name

Paul Adair

Telephone number

020 7982 1236

If a connected EFM, name of offeree/offeror with which connected

N/A

If a connected EFM, state nature of connection (Note 10)

N/A

Β 

Β 

This information is provided by RNS
The company news service from the London Stock Exchange
Β 
END
Β 
Β 
ISEPKADBQBDDADD
Date   Source Headline
1st Mar 20178:51 amRNSPress Release
27th Feb 201710:45 amRNSPress Release
24th Feb 20172:19 pmRNSPress Release
22nd Feb 20177:00 amRNSCancellation of UK Listing
31st Jan 20172:56 pmRNSFourth Quarter and Full-Year 2016 Results
24th Nov 20153:20 pmRNSForm 8.3 - Pfizer Inc
24th Nov 20153:19 pmRNSForm 8.3 - Pfizer, Inc.
24th Nov 201512:14 pmRNSForm 38.5(b) - Pfizer Inc
24th Nov 201511:49 amRNSForm 8.1a - Pfizer Inc
24th Nov 201511:46 amRNSForm 38.5(a) - Pfizer Inc
24th Nov 201510:41 amRNSRule 38.5 - Pfizer INC
24th Nov 20157:00 amRNSForm 38.5(b) - Pfizer Inc
23rd Nov 20156:11 pmRNSForm 38.5(a) - Pfizer Inc
23rd Nov 20155:58 pmRNSForm 8.1a - Pfizer Inc
23rd Nov 20153:40 pmRNSForm 8.3 - PFIZER INC
23rd Nov 20153:34 pmRNSForm 8.3 - Pfizer Inc Amendment
23rd Nov 20153:31 pmRNSForm 8.3 - Pfizer Inc
23rd Nov 20153:31 pmRNSForm 8.3 - Pfizer Inc
23rd Nov 20153:28 pmRNSForm 8.3 - ALLERGAN PLC
23rd Nov 20153:21 pmRNSForm 8.3 - Pfizer, Inc.
23rd Nov 20152:56 pmRNSForm 8.3 - Pfizer Inc
23rd Nov 20152:39 pmRNSForm 8.3 - Pfizer Inc
23rd Nov 20152:29 pmRNSForm 8.3 - Allergan Plc
23rd Nov 201512:16 pmRNSForm 8.1 - [Pfizer Inc.]
23rd Nov 201512:04 pmRNSForm 38.5a
23rd Nov 201511:57 amRNSForm 38.5b
23rd Nov 201511:55 amRNSForm 38.5b
23rd Nov 201511:55 amRNSForm 8.3 - Pfizer Inc.
23rd Nov 201510:58 amRNSRule 38.5 - Pfizer INC
23rd Nov 201510:58 amRNSRule 38.5 - Pfizer INC
20th Nov 20153:43 pmRNSForm 8.3 - Pfizer Inc.
20th Nov 20153:34 pmRNSForm 8.3 - Pfizer Inc
20th Nov 20153:25 pmRNSForm 8.3 - Allergan plc
20th Nov 20153:21 pmRNSForm 8.3 - PFIZER INC
20th Nov 20153:17 pmRNSForm 8.3 - ALLERGAN PLC
20th Nov 20153:14 pmRNSForm 8.3 - Pfizer Inc
20th Nov 20153:11 pmRNSForm 8.3 - [PFIZER INC]
20th Nov 20153:07 pmRNSForm 8.3 - Pfizer Inc
20th Nov 20152:58 pmRNSForm 8.3 - Allergan plc
20th Nov 20152:57 pmRNSRule 38.5 - Replacement Pfizer INC
20th Nov 20152:52 pmRNSForm 8.3 - Allergan Plc
20th Nov 20152:44 pmRNSForm 8.3 - Pfizer, Inc.
20th Nov 201512:14 pmRNSForm 8.1 - [Pfizer Inc]
20th Nov 201511:57 amRNSForm 38.5b
20th Nov 201511:55 amRNSForm 8.3 - Pfizer Inc.
20th Nov 201511:53 amRNSForm 38.5b
20th Nov 201511:53 amRNSForm 38.5(b) - Pfizer Inc
20th Nov 201511:52 amRNSForm 38.5a
20th Nov 201511:18 amRNSForm 38.5(a) - Pfizer Inc
20th Nov 201510:37 amRNSRule 38.5 - Pfizer INC

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.